Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Drugs by status
Approved for this indication (29)
- fluorodopa
- selegiline
- pramipexole
- carbidopa
- istradefylline
- rivastigmine
- valerianae radix
- tolcapone
- opicapone
- ropinirole
- pimavanserin
- biperiden
- apomorphine
- rasagiline
- atropine
- cabergoline
- safinamide
- procyclidine hydrochloride
- entacapone
- caramiphen hydrochloride
- ethopropazine
- levodopa
- rotigotine
- bromocriptine
- trihexyphenidyl
- amantadine
- cycrimine
- benzatropine
- metixene
Phase 4 trials (47)
- lubiprostone
- trehalose
- zoledronic acid
- donepezil
- vortioxetine
- d-serine
- trimethobenzamide
- memantine
- zonisamide
- sildenafil
- soybean
- terazosin
- rimabotulinumtoxinB
- mirabegron
- whey protein
- tadalafil
- nicotine
- sitagliptin
- Lactobacillus acidophilus
- varenicline
- propofol
- atomoxetine
- bifidobacterium animalis
- naltrexone
- dexmedetomidine
- droxidopa
- blood plasma
- fesoterodine
- desmopressin
- motilitone
- +17 more
Phase 3 trials (69)
- fexofenadine
- ambroxol
- quinidine
- prasinezumab
- buspirone
- procaine benzylpenicillin
- ampreloxetine
- sumanirole
- onabotulinumtoxinA
- bhv-8000
- tozadenant
- dnl151
- eszopiclone
- creatine
- 18f-fp-dtbz
- msk-da01
- dipraglurant
- exenatide
- metformin
- Tavapadon
- telmisartan
- sarizotan
- roucongrong
- domperidone
- tyramine
- heshouwu
- omeprazole
- pitolisant
- oxaloacetate
- cvn424
- +39 more
Phase 2 trials (208)
- reishi mushroom
- ketamine
- cere-120
- pioglitazone
- prosavin
- sulforaphane
- vatiquinone
- ent-01
- tocotrienol
- Vutiglabridin
- tak-071
- pym50028
- flumazenil
- cpl500036
- ucb-j
- 123i b-cit
- e2027
- arundic acid
- glutathione
- ec5026
- aci-7104.056
- btrx-246040
- ipratropium
- iti-214
- remimazolam
- grf6021
- 123i 5-ia
- 124i-meta-iodobenzylguanidine
- kdt-3594
- insulin human
- +178 more
Phase 1 trials (121)
- 123i mzint
- op-801
- ux-da001
- fb-101
- aluminum hydroxide
- ica07
- her-096
- ave8112
- plantago ovata
- rosuvastatin
- Megasphaera massiliensis
- resveratrol
- pf-06412562
- warfarin
- spartalizumab
- febuxostat
- lu ae04621
- flortaucipir
- acr325
- vitis vinifera
- xenon-129
- biib094
- rq-00000010
- lu af82422
- [18f]mni-1216
- copper
- xc130-a10h
- repaglinide
- pf-06669571
- v81444
- +91 more
Other trials (65)
- oleic monoethanolamide
- l-carnosine
- lactobacillus rhamnosus
- Piribedil
- saffron
- propranolol
- hericium erinaceus mycelia
- cocoa bean
- tong-jiang
- clostridium butyricum
- lactulose
- amoxicillin
- bacillus subtilis
- raav-gad
- clozapine
- lactobacillus plantarum
- ketone monoester
- autologous umbilical cord blood
- leucine
- esketamine
- i-123-5-ia85380
- wheat
- 18f pe2i
- magnesium
- glucose
- apigenin
- erythromycin
- vanillin
- bifidobacterium longum
- psyllium
- +35 more
Organizations
Organization Involved with Phase 4 Indications (131)
- Agenzia Italiana del Farmaco
- University of Perugia
- Qilu Pharmaceutical Co., Ltd.
- University of Lille
- University of Quebec
- Rowan University
- I.R.C.C.S. Fondazione Santa Lucia
- Rouen Normandy University
- Methodist Cancer Center, Houston, Texas
- Soonchunhyang University
- University Clermont Auvergne
- University of South Florida
- Laval University
- National Institute of Mental Health (NIMH)
- Boehringer Ingelheim
- University of Poitiers
- University of Caen-Normandie
- Lundbeck
- EvergreenHealth
- Parkinson's Disease and Movement Disorder Center of Boca Raton
- University of Maryland
- University of Kansas
- Sungkyunkwan University
- Qualissima
- Korea University
- University of Picardie Jules Verne
- University of Wisconsin
- University of Groningen
- University of Rennes
- Oslo Metropolitan University
- +101 more
Organization Involved with Phase 3 Indications (154)
- Fudan University
- Cerevel Therapeutics, LLC
- National Institute of Mental Health and Neuro Sciences, India
- Merck Serono
- University of Newfoundland
- Apollo Hospitals, Chennai, India
- Rutgers University
- Deutsche Parkinson Vereinigung
- Nizam's Institute of Medical Sciences, Hyderabad, India
- M.S. Ramaiah Medical College, Bangalore, India
- Navidea Biopharmaceuticals
- Mallikatta Neuro and Research Centre, Mangalore
- PPD
- China Ministry of Health
- Rehabiliation Hospital, Lasi
- Britannia Pharmaceuticals Ltd.
- Abbott
- J.J Hospital, Mumbai
- Ospedale di Viareggio, Viareggio
- University of Toulouse
- Medical University Innsbruck
- Zhejiang University
- Takeda
- Elias University
- NIMHANS, Bangalore
- Owaisi Hospital & Research Centre
- Cephalon
- Kyowa Hakko Kirin
- Osmotica Pharmaceutical
- Tel Aviv University
- +124 more
Organization Involved with Phase 2 Indications (210)
- Bayer
- Centro Nacional Producción Animales de Laboratorio (CENPALAB)
- Aston University
- Renishaw plc.
- Prevail Therapeutics
- German Parkinson Society
- Apotex
- European Commission
- Peptron, Inc.
- University of Colorado
- University of Gothenburg
- University of California, San Diego
- Cita NeuroPharmaceuticals
- Government of Taiwan
- Taipei Medical University
- Theranexus
- Ligand Pharmaceuticals
- Phytopharm
- Cavion LLC
- B&A Therapeutics
- Alkahest, Inc.
- University of Queensland
- Clene Nanomedicine
- Wellness Health & Pharmaceuticals, Inc.
- Contera Pharma
- Memorial Medical Center
- Juvantia Pharma Ltd
- Tools4Patient
- VistaGen Therapeutics, Inc.
- Parkinson Study Group
- +180 more
Organization Involved with Phase 1 Indications (80)
- Lambda Therapeutic Research Ltd
- Celavie Biosciences, LLC
- Allife Medical Science and Technology Co., Ltd.
- Neurocrine Biosciences
- Medical Research Foundation, Oregon
- Sponsor GmbH
- Virginia Commonwealth University
- RaQualia Pharma Inc.
- Serina Therapeutics
- The Swedish Research Council
- Vastra Gotaland Region
- Bracket Global
- Kainos Medicine Inc.
- Cyto Therapeutics Pty Limited
- Denali Therapeutics Inc.
- Ionis Pharmaceuticals, Inc.
- Algorithme Pharma Inc
- Covance
- 1ST Biotherapeutics, Inc.
- Prosenex Ambulatorium BetriebsgmbH
- State University of New York, Buffalo
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Io Therapeutics
- National Center for Advancing Translational Science (NCATS)
- Dizlin Medical Design AB
- Affiris AG
- Alexza Pharmaceuticals, Inc.
- Nebraska Neuroscience Alliance
- University of North Carolina at Chapel Hill
- Veristat, Inc.
- +50 more
Organization Involved with Other Experimental Indications (37)
- Institut de Myologie, France
- National University of Malaysia
- Slovak Academy of Sciences
- Government of Belgium
- University of Bordeaux
- University of Malaya
- University of Salerno
- Saarland University
- Roxane Laboratories
- Johnson and Johnson
- Julius-Maximilians University
- Association Institut de Myologie
- Aix-University of Marseille
- University of Bergen
- the Flanders Institute for Biotechnology
- Bioengineering Center, Grape King Bio
- Ain Shams University
- Professor Lu Neurological Clinic
- Colorado Springs Neurological Associates
- Abecma
- Ghent University
- SFBC Anapharm
- University of Virginia
- New York College of Osteopathic Medicine
- University of Montpellier
- Neuromed IRCCS
- National Parkinson Foundation
- NeuroHealth
- European Parkinson Therapy Centre
- Northwell Health
- +7 more